Over the past several years, glomerular diseases have garnered
significant attention from the nephrology industry, largely driven
by the persistent unmet needs present for patients grappling with
these rare conditions. With a range of approved products and a
thriving pipeline, IgA nephropathy (IgAN) has emerged as a focal
point of innovation in the field. The latest milestone in this
trajectory is the European Medicines Agency’s (EMA) conditional
approval of Travere/CSL Vifor's FILSPARITM (sparsentan) for the
treatment of primary IgAN patients with a urine protein excretion
≥1.0g/day (or urine protein-to-creatinine ratio ≥0.75 g/g),
announced on April 24, 2024.
Top of Form
Findings from Spherix Global Insights' second annual Patient
Chart DynamixTM: IgA Nephropathy (EU5) study reveal a dynamic
landscape, as evidenced by the analysis of 514 IgAN patient records
collected in collaboration with 272 nephrologists across the United
Kingdom, Germany, Italy, Spain, and France. The data underscores
ongoing evolution in the approach to IgAN treatment, marked by a
rising adoption of SGLT2 inhibitors and growing utilization of
Kinpeygo in Germany. Of note, EU5 physicians continue to seek to
minimize the use of systemic corticosteroids and other
immunosuppressive agents in this patient population, highlighting
the opportunity for newer agents to further evolve the treatment
paradigm.
Despite the increased utilization of SGLT2 inhibitors in earlier
lines of therapy, often coupled with ACE inhibitors and ARBs,
approximately half of patients persist with proteinuria levels
surpassing 1.0g/day. This underscores the pressing need for novel
therapies to enhance patient outcomes effectively. Moreover, there
is a growing demand for products that demonstrate substantial
preservation of kidney function, as physicians anticipate that a
majority of IgAN patients will eventually require dialysis.
When surveyed early in 2024, EU5 nephrologists indicated the
highest level of familiarity with sparsentan among the pipeline
agents under development for IgAN. As the pioneering
non-immunosuppressive therapy poised for approval, sparsentan also
boasted the highest rates of patient candidacy among the audited
patients, followed by atrasentan (Novartis/Chinook), ravulizumab
(Alexion), and iptacopan (Novartis).
Top of Form
When considering patient candidacy for the various pipeline
therapies, physicians often indicate that they will base their
treatment decisions on comorbidities, proteinuria levels, rate of
eGFR decline, and a multitude of other factors. Notably, some
nephrologists are not perceiving a large difference between
FILSPARITM (sparsentan), a dual endothelin angiotensin receptor
antagonist (DEARA), and atrasentan, an oral endothelin-A receptor
antagonist (ERA). This lack of perceived differentiation, despite
the mechanism of action and expected efficacy of the agents,
highlights the potential competitive dynamics that the market will
face once additional products are launched, and further underscores
the importance of physician education to help advance patient
care.
Spherix's recent Market DynamixTM: Rare Glomerular Diseases
(EU5) study offers an additional comprehensive examination of
the evolving landscape across various glomerular diseases to
further benchmark the relative unmet needs and excitement around
the pipelines. In this study, 206 EU5 nephrologists shared their
perspectives on the evolving market dynamics in IgAN, focal
segmental glomerulosclerosis (FSGS), C3 glomerulopathy (C3G),
ANCA-associated vasculitis (AAV), Alport syndrome, IgA vasculitis
(IgAV), membranous nephropathy, lupus nephritis, aHUS, and minimal
change disease (MCD). The findings revealed numerous challenges
faced by respondents in treating patients with rare kidney
diseases, notably a deficiency in effective treatment options.
Top of FormSpherix will
continue to track the developing IgAN markets in the US, EU, Japan,
and China. With the anticipated introduction of new therapies from
Novartis/Chinook, Alexion, Vera Therapeutics, Otsuka, Ionis/Roche,
Alnylam, and other companies, the landscape of IgAN treatment is
poised for further evolution, prompting ongoing changes in the
treatment paradigm.
Patient Chart Dynamix™ is an independent, data-driven
service unveiling real patient management patterns through rigorous
analysis of large-scale patient chart audits. Insights reveal the
“why” behind treatment decisions, include year over year trending
to quantify key aspects of market evolution, and integrate
specialists’ attitudinal & demographic data to highlight
differences between stated and actual treatment patterns.Top of
Form
Market Dynamix™ is an independent service providing
analysis of markets anticipated to experience a paradigm shift
within the next three to five years. Insights highlight market
size, current treatment approaches, unmet needs, and expert
opinions on the likely disruption introduced by pipeline
agents.
About Spherix Global Insights
Spherix Global Insights is a leading provider of market
research, business intelligence and advisory services to the global
life sciences industry. The company’s unique service offerings are
powered by deep therapeutic knowledge, the Spherix Network
specialty physician panel, and commercially relevant analyses to
enable strategic decision-making by our valued customers.
A trusted advisor and industry thought leader, Spherix Global
Insights provides specialized market expertise in six (6) focused
therapeutic areas including: dermatology, gastroenterology,
nephrology, neurology, rheumatology, and ophthalmology.
To learn more about Spherix Global Insights,
visit spherixglobalinsights.com or connect
through LinkedIn.
For more details on Spherix’s primary market research reports
and interactive dashboard offerings, visit or register
here: https://clientportal.spherixglobalinsights.com
NOTICE: All company, brand or product names in this press
release are trademarks of their respective holders. The findings
and opinions expressed within are based on Spherix Global Insight’s
analysis and do not imply a relationship with or endorse.
Meghan Weiss, Nephrology Franchise Head
Spherix Global Insights
484-879-4284
Meghan.Weiss@spherixglobalinsights.com